The purpose of the current study is to accelerate the use of a clinically available
therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19
addressing a serious and emergent unmet medical need.
This is a randomized, double-blind study of atovaquone therapy in adult participants
hospitalized with COVID-19. Approximately 60 participants who meet all eligibility criteria
may be randomized in a 2:1 atovaquone/placebo ratio into one of the following treatment
groups:
Treatment Group 1: continued standard of care therapy together with an oral dose of 1500 mg
atovaquone twice daily (administered with a meal or snack) for up to 10 days
Treatment Group 2: continued standard of care therapy together with matching placebo